NOVEL ANTICOAGULANTS & ANTIDOTES
TRADITIONAL ANTICOAGULANTS & THEIR PROBLEMS
The blood coagulation cascade must be regulated in large numbers of health care situations, including during surgery, dialysis treatments, and in thrombotic diseases that can lead to deep clots, stroke, and death. Conventional intravenous anticoagulant drugs such as heparin are associated with serious side-effects and suffer from unpredictable dose response, and their biological activities are difficult to reverse (antidotes are unavailable, non-specific, have harmful side-effects, or are very expensive)
OUR TECHNOLOGY
Using a new molecular engineering strategy, we have designed, created, and tested a family of functional RNA origami anticoagulants and a specific reversal agent to address the critical problems of traditional anticoagulants for better human health.
Specific – Our molecule specifically binds to targeted protein, offering precise control action and reduction of complications
Fast “On-Off” Action – With fast, safe and specific antidote, we are able to control “on-off” action of drug as we needed
Long-Circulation – Therapeutic agents with optimal size provide long-circulation times in body, offering benefits in long, complicated surgical procedures.
Heparin-Sensitive Patients – Our drugs would fill a void in health care for heparin-resistant and heparin-sensitive patients, and eradication of who are at risk for heparin-induced thrombocytopenia.
Products for Kidney Failure Patients – We rationally designed the optimal drug’s size to avoid renal filtration.
